Indivior aims to move primary listing from London to New York

Unlock the Editor’s Digest for free

Drugmaker Indivior said it was aiming to move its primary listing from London to New York and had begun canvassing shareholder support for the switch, in the latest blow to the UK market.

The move would bring several benefits, including attracting more US investors and, eventually, inclusion in major stock market indices, Indivior said on Thursday alongside its full-year results.

The group, whose products include treatments for opioid use disorder and schizophrenia, said it would move the listing in the summer if it secures shareholders’ backing.

“If the consultations indicate a strong level of support from shareholders, the group intends to put forward a formal resolution that would facilitate a primary US listing in the summer of 2024,” Indivior said.

Shares in the company, which was spun out of the consumer goods group Reckitt Benckiser in 2014, jumped by almost 20 per cent in early trading.

Articles You May Like

Biden convenes G7 in response to Iran’s ‘brazen’ attack on Israel
Next UK government will face biggest challenge since war, warns Ken Clarke
Asian emerging market currencies come under pressure from strong dollar
The Biden dilemma on Israel
Regional bank earnings may expose critical weaknesses, former FDIC Chair Sheila Bair warns